BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Appoints Interim Chief Financial Officer, Changes Auditor

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, announced that Jonathan Tegge, a member of Brio Financial Group, will shoulder the role of interim CFO effective Dec. 12, 2022. The announcement accompanied the news that InMed has signed a service contract with Brio Financial Group to provide senior financial leadership and bookkeeping services. A financial and management consulting group based in New Jersey, Brio outsources financial management and financial reporting support to small- and middle-market entities. Currently, the Brio team provides consulting services to some 50 private and publicly traded companies. InMed also stated that its auditor, KPMG LLP; InMed’s audit committee of the company’s board of directors approved Marcum LLP as the new company auditor. “We are delighted to engage Marcum as the company’s new auditors,” said InMed Pharmaceuticals CEO Eric A. Adams in the press release. “We believe that Marcum’s breadth of expertise and its focus on mid-sized companies, including cross-border operations, makes Marcum well suited to support our efforts to deliver the high level of financial transparency and reporting to which our shareholders are accustomed.”

To view the full press release, visit https://ibn.fm/IKVmV

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. The company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, please visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork